Sputtr.com | Alternative Search Engine

Sorafenib

Sorafenib for the treatment of advanced hepatocellular carcinoma

CONFIDENTIAL Issue date: May 2010 Review date: November 2012 NICE technology appraisal guidance 189 Sorafenib for the treatment of advanced hepatocellular carcinoma This guidance was developed using the single technology appraisal process

HIGHLIGHTS OF PRESCRIBING INFORMATION

Female patients should also be advised against breast-feeding while receiving NEXAVAR [see Warnings and Precautions (5.11)] _____ 17.5 FDA-approved Patient Labeling Patient Information: NEXAVAR (NEX-A-VAR) (sorafenib) tablets, oral Read the Patient ...

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not ...

Bayer Response Nexavar STN 21923/012 14 Oct 11 9 Effect of Cytochrome P450 Inhibitors on Sorafenib Ketoconazole, a strong inhibitor of CYP3A4 and P-glycoprotein, administered at a dose of 400 mg once daily for 7 days did not alter the mean AUC of a single oral dose of NEXAVAR 50 mg in healthy volunteers.

CIGNA's pharmacy coverage position on Sorafenib (Nexavar)

C IGNA M EDICAL C OVERAGE P OLICY The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

Pharmacy Medical Necessity Guidelines: Nexavar (sorafenib)

Pharmacy Medical Necessity Guidelines Nexavar® (sorafenib) Pharmacy Medical Necessity Guidelines: Nexavar (sorafenib)

Sorafenib Nexavar (HCC)

Committee to Evaluate Drugs (CED) Recommendations and Reasons This document posted January 2009 Sorafenib (for hepatocellular carcinoma) Product: SORAFENIB (Nexavar®) 200mg tablet Class of drugs: Multi-kinase inhibitor; anti-cancer agent Indication: Treatment of hepatocellular carcinoma (HCC ...

GIDEON (Global Investigation of therapeutic DEcisions in HCC ...

GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study first interim results: sorafenib dosing across regions and disease subgroups

the Combination of Sorafenib and Tanespimycin Safety ...

Cancer Therapy: Clinical Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin Ulka N. Vaishampayan

JPET # 175034 Role of Breast Cancer Resistance Protein ...

JPET # 175034 Running Title Page Distribution of sorafenib to the brain is limited by BCRP Corresponding Author William F. Elmquist, Department of Pharmaceutics, University of Minnesota, 9-177 Weaver

Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95 ...

Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95 Dependent and -Independent Mechanisms Teneille Walker, Clint Mitchell, Margaret A. Park, Adly Yacoub, Martin Graf,